Guardant Health Outcomes Model Confirms the Public Health Importance of Enhanced Colorectal Cancer Screening Outcomes with High Adherence Strategies

Research Study Accepted for Publication Demonstrates Efficacy of Blood-Based Tests for CRC Screening

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the acceptance of its health outcomes study, the CAN-SCREEN model, for publication in the Journal of Medical Economics, highlighting the importance of combining clinically meaningful screening performance with high patient adherence in colorectal cancer (CRC) screening to optimize CRC-related health outcomes.

The CAN-SCREEN model addresses the significant limitations of existing models, which often assume absolute adherence to screening protocols. These assumptions fail to accurately predict population-level health outcomes, overlooking the real-world challenges and preferences of patients. Guardant Health's innovative model accounts for both clinical efficacy and adherence in determining CRC incidence and mortality rates.

A key benefit of Guardant Health’s blood-based screening test, Shield™, is the potential to reduce CRC-related mortality due to its high adherence. This non-invasive screening modality is designed to maximize patient adherence, offering a more accessible and preferable option than traditional methods. By integrating this blood-based test into existing screening programs, the CAN-SCREEN model predicts a significant reduction in CRC-related deaths, particularly among previously unscreened populations. The model also predicts that patients screened with blood-based testing gained more life years, compared to those screened with FIT or mtsDNA.

“At Guardant Health, our mission is to enhance cancer detection and improve patient outcomes through innovative solutions,” said AmirAli Talasaz, Co-CEO of Guardant Health. “The CAN-SCREEN model's findings reinforce the critical role of adherence in CRC screening strategies. By leveraging our blood-based test, we are poised to substantially impact CRC screening adherence and ultimately save lives.”

Guardant Health remains committed to advancing precision oncology through groundbreaking research and state-of-the-art diagnostic tools. The CAN-SCREEN model represents a pivotal step forward in optimizing CRC screening strategies, ensuring that more patients benefit from early detection and timely intervention.

About Guardant Health
Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer. For more information, visit guardanthealth.com and follow the company on LinkedIn, X (Twitter) and Facebook.

References
Forbes, S. P., Yay Donderici, E., Zhang, N., et al. (2024). Population health outcomes of blood-based screening for colorectal cancer in comparison to current screening modalities: insights from a discrete-event simulation model incorporating longitudinal adherence. Journal of Medical Economics, 1–40. https://doi.org/10.1080/13696998.2024.2382036